Journal of Vaccines & Vaccination

Molecular Express, Inc., Rancho Domínguez, California, USA

Biography

Gary Fujii, American Biophysical chemist. Achievements include patents for delivery vehicles with amphiphile-associated active ingredients, for composition and method of use for liposome encapsulated compounds for neutron (capture) therapy, and for method of making liposomes with improved stability during drying. Member American Crystallographic Association, Protein Society.

Publications

• Research   
  SHIV Virus-Like Particles (VLPs) Vaccination Induces Partial Protection from SHIV Challenge in a Rhesus Macaque Model
  Author(s): Ethan Poteet, Phoebe Lewis, Zhiyin Yu, Changyi Chen, Guojun Yang, Pramod N Nehete, K Jagannadha Sastry, Gary Fujii and Qizhi Yao*
  
  Simian/Human immunodeficiency virus (SHIV) virus-like particles (VLPs) composed of SIV Gag, HIVsf162 gp120/ gp41 envelope, and human CD40L are whole pseudovirion vaccines capable of eliciting both humoral and cellular immunity. We immunized four rhesus macaques by intranasal prime and four sub-cheek boosts with VLPs adjuvanted with conjugatable adjuvant lipid vesicles containing monophosphoryl lipid A (MPLA), and compared their immune parameters to those in five unimmunized control macaques. Increased plasma antibody titers to SIV Gag were observed in all four immunized macaques and increased sf162 gp140 titers were observed in three of the four with one macaque (10-195) maintaining sustained anti-Env antibody levels. Compared to controls, a significant increase in memory B cells and CD4+ central memory T cells was detected in the immunized group. Among these, elevated Gagspecific CD1.. View more»
  

  Abstract PDF